このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Tyra Biosciences 過去の業績

過去基準チェック /06

Tyra Biosciencesの収益は年平均-46.8%で減少しているが、Biotechs業界はgrowingで15.5%年平均の収益となった。

主要情報

-46.8%

収益成長率

39.1%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-19.4%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Mar 31

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Dec 15

収支内訳

Tyra Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:TYRA 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-75	19	69
31 Dec 23	-69	17	63
30 Sep 23	-59	17	52
30 Jun 23	-51	15	44
31 Mar 23	-52	15	44
31 Dec 22	-55	16	43
30 Sep 22	-52	14	40
30 Jun 22	-46	12	34
31 Mar 22	-37	10	27
31 Dec 21	-26	6	21
30 Sep 21	-20	4	16
30 Jun 21	-16	3	13
31 Mar 21	-12	2	10
31 Dec 20	-9	2	7

質の高い収益: TYRAは現在利益が出ていません。

利益率の向上: TYRAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: TYRAは利益が出ておらず、過去 5 年間で損失は年間46.8%の割合で増加しています。

成長の加速: TYRAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: TYRAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: TYRAは現在利益が出ていないため、自己資本利益率 ( -19.35% ) はマイナスです。

Tyra Biosciences 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Now 29% overvalued

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. Announces Board Changes

Tyra Biosciences, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$24.20

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. announced that it expects to receive $200 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC

New minor risk - Share price stability

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

Price target decreased by 9.0% to US$22.20

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Price target increased by 8.4% to US$24.40

Tyra Biosciences Announces Fda Orphan Drug Designation for Tyra-300 for the Treatment of Achondroplasia

Co-Founder exercised options and sold US$286k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Co-Founder & COO exercised options and sold US$350k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.3% to US$19.25

Tyra Biosciences, Inc. Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

High number of new directors

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$20.00

Tyra Biosciences Announces Chief Financial Officer Changes

Tyra Biosciences, Inc. Announces Appointment of Ali Fawaz as General Counsel and Secretary

Tyra Biosciences GAAP EPS of -$0.36

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 2000 Growth Index

High number of new directors

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

High number of new directors

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Tyra Biosciences, Inc. has completed an IPO in the amount of $172.8 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06